Belgian Pharma Stock News

Viohalco (ENXTBR:VIO) has drawn fresh attention after a recent pullback, with the share price down 1.2% on the day and roughly 8% over the past month. Short term momentum for Viohalco looks weaker, with the share price down 3.5% over the past week and roughly 14.9% over three months. Yet the year to date share price return of 35.8% and a 1 year total shareholder return of about 141.6% still point to a stock that has rewarded patient holders even through recent volatility. Broaden your...

Brederode reported half year 2026 results showing revenue of €309.78 million and net income of €347.64 million, compared with a revenue loss and net loss for the same period in 2025, with basic earnings per share from continuing operations at €11.86 versus a prior basic loss per share. The swing from negative revenue and a loss to positive revenue and profit reflects a sharp change in Brederode’s reported performance over the past year. Attention now turns to how this sharp earnings change...

Aedifica/SA: earnings jump, dividend guidance and investor focus Aedifica/SA (ENXTBR:AED) just paired a sharp move in half year 2026 results with fresh dividend guidance and an upcoming appearance at the EPRA Milan Conference on 8 September 2026. The healthcare focused real estate group reported half year sales of €292.31 million and net income of €509.57 million, both well above the prior year period, while basic earnings per share reached €7.28 from continuing operations. Management also...

Ageas has completed the sale of its 30.95% stake in Maybank Ageas Holdings Berhad to Maybank for €1.1b, generating a €464m net capital gain after tax and valuing the Malaysian joint venture at €3.5b. The deal lifts Ageas's Solvency II ratio by 23 percentage points and gives the insurer more room to allocate capital across dividends, investments and possible future deals. This article examines how Ageas's investment narrative is reshaped by this €1.1b disposal and the step up in solvency...

CEO transition and fresh earnings put D'Ieteren Group in focus D'Ieteren Group (ENXTBR:DIE) has moved into the spotlight after appointing incoming chief executive officer Eric Machiels and releasing half year 2026 results that showed higher net income and earnings per share, alongside slightly softer sales. D'Ieteren Group shares trade at €170.3 after a 1-day share price return of 1.73%, even though the stock has slipped over the past week and month. A 10.16% year-to-date share price gain and...

Viohalco stock has turned a long holding period into a strong outcome over the past five years, yet the broader valuation checks now lean toward the shares looking expensive rather than like an obvious bargain. Over five years, Viohalco has returned about 276%, which puts the recent slide into perspective and raises the question of how much of the story is already in the price. Future earnings and cash generation from its metals and industrial operations can support the current market value,...

UCB (ENXTBR:UCB) just received Breakthrough Therapy Designation from the FDA for CIMZIA in antiphospholipid syndrome related pregnancy complications. Investors now have a fresh R&D catalyst to weigh against recent share performance. In the short term, UCB’s 1-day share price return of 1.93% and latest close at €205.6 only partly offset a 90-day share price decline of 25.21%. However, the 3-year total shareholder return of 148.78% indicates that the longer-term momentum has been much stronger...

Recent price pressure in Elia Group (ENXTBR:ELI), with the share down about 11% over the past month and 14% over the past 3 months, has pushed the grid operator back onto investor watchlists. At around €117.0, Elia Group’s recent share price weakness follows a period where shorter term momentum has faded. However, the year-to-date share price return of 4.28% and 1-year total shareholder return of 24.14% still present a stronger long run picture. Scan how Elia Group’s recent pullback compares...

Earnings jump puts Gimv in focus Gimv (ENXTBR:GIMB) has moved into the spotlight after reporting half year net income of €148.34 million and basic earnings per share of €4.03, both higher than the prior period. The latest half year figures arrive as Gimv's share price edges higher, with a 1 day share price return of 2.25% and a 1 month share price return of 3.53%, while the 3 year total shareholder return of 26.11% points to momentum that has built gradually over time rather than in a single...

Aedifica/SA (ENXTBR:AED) announced significantly improved half year 2026 results alongside a higher proposed dividend for 2026. The healthcare real estate group paired the earnings release with guidance on a richer cash return profile to shareholders from 2026. Management described the upgraded 2026 payout as aligned with the stronger first half 2026 performance indicators reported today. The stronger half year figures and higher 2026 dividend proposal only tell part of the Aedifica story...

Brederode has been trading like a problem child that quietly fixed many of its issues. The share price has barely shifted over the past week, yet the latest half year release shows earnings power that looks very different to the firm that reported losses in early 2025. The headline this time is profit quality, not hype. Basic earnings per share reached €11.86 for the first half and trail the past year at €20.94, backed by €613.72m in net income from continuing operations. For a stock on...

Eurozone power and utility stocks are suddenly in the spotlight as the ECB pushes rates to 2.5% and fresh conflict risk keeps oil above $105 and gas prices elevated. Higher funding costs and stubborn inflation are reshaping how investors think about regulated grids and power producers. This article unpacks that story and walks through 3 European regulated utilities and power stocks that appear especially exposed to these shocks. The stocks highlighted below are just a starting sample, and the...

Investors came in treating D'Ieteren Group as a high‑multiple compounder with something to prove after a choppy few weeks for the share price. The stock is down about 4% over 7 days and 6% over a month to €167.40. The headline from these half year numbers is simple: profit did the heavy lifting, not sales. Net income for H1 landed at €256.9m on revenue of €3,930.6m, keeping the earnings story alive even as top line momentum softened. For a stock already on a premium P/E, that profit...

Lotus Bakeries has delivered a strong run over the past five years, yet both its intrinsic value estimate and market multiples currently point to a stock trading at a premium rather than an obvious bargain. Over the past 5 years, Lotus Bakeries shares have returned about 124.7%, which sets a high bar for anyone buying in today. The business can support elevated expectations if it keeps converting growth into resilient cash flows. Any slowdown in those cash flows or pressure on profitability...

Onward Medical walked into this earnings day with a warm tailwind. The stock had gained about 20% over the past month and more than 15% across the last week, so expectations were already elevated. The headline from the release is simple and emotional. The company is still burning cash hard, with a net loss of €24.7m in the first half of 2026, while the share price reflects a rich story stock on a steep price to sales multiple of 23.1x. That clash between heavy losses and lofty valuation is...

Sofina Société Anonyme reported half year 2026 results, moving from a net loss of €393.95 million a year earlier to net income of €857.5 million, with basic earnings per share from continuing operations at €24.198 and diluted earnings per share at €23.5251. The swing back to profit signals a notable shift in underlying performance quality, since both basic and diluted earnings per share from continuing operations turned positive in the period. With this earnings turnaround now on the table,...

DEME Group has delivered strong share gains over the past three years, yet both an intrinsic value estimate and market multiples still point to the stock trading at a discount to what its cash flows and fundamentals may support. That mix of a solid run in the share price and valuation models still flagging potential undervaluation is what investors now need to weigh. Over the past 3 years the stock has returned about 83%, which means anyone looking at DEME Group today is assessing a business...

Why Spadel’s latest half year report matters now Spadel (ENXTBR:SPA) just released half year figures to June 30, 2026, with sales reported at €219.87 million and net income at €32.58 million, compared with €199.76 million and €26.78 million a year earlier. Spadel’s latest half year report lands after an already strong run, with the share price up 52.54% year to date and a 1 year total shareholder return of 64.90% that builds on a 3 year total shareholder return of 124.38%. Scan beyond Spadel...

The market has been leaning away from Texaf for weeks, with the share price down about 8% over three months. Yet the latest half year figures tell a calmer story. Revenue reached €18.9m and basic earnings per share came in at €1.07, which keeps the business firmly profitable even if not explosive. The real flashpoint is valuation. At a trailing P/E of 16.9x and a dividend yield near 4.9% that is not fully covered by free cash flow, the question now is how much patience investors have for this...

Gimv NV reported half year results for the period ended June 30, 2026, with net income of €148.34 million and basic and diluted earnings per share from continuing operations of €4.03, compared with €85.8 million and €2.33 a year earlier. The sharp step up in earnings per share indicates that Gimv’s recent investment and operating decisions were associated with materially higher profitability over the past twelve months. Next is an examination of how this earnings increase at Gimv,...

Solvay (ENXTBR:SOLB) is expanding its Taiwan capacity for ultra pure hydrogen peroxide from 35,000 tonnes to more than 70,000 tonnes in order to support chipmaking customers such as TSMC and grow its electronics focused peroxide business. For investors watching Solvay, the expansion comes as the share price has been relatively muted, with a 1-day share price return of 0.93% and a 90-day share price return of 1.08%. At the same time, the 1-year total shareholder return of 1.68% and 3-year...

As European markets navigate mixed economic signals and geopolitical developments, the pan-European STOXX Europe 600 Index remains relatively stable, reflecting a cautious investor sentiment. Against this backdrop, dividend stocks can offer a potential source of steady income for investors seeking stability amid market fluctuations.

Shareholders in ageas SA/NV ( EBR:AGS ) may be thrilled to learn that the analysts have just delivered a major upgrade...

Care Property Invest stock has barely budged over the past month, yet the latest earnings forced investors to confront a gap between income headlines and cash reality. Reported earnings over the last year look strong and help support an 8.05% dividend yield, while the stock trades on a P/E of 8.5x against higher peer and sector averages. The catch is that a large one off gain lifted those earnings. Today’s muted reaction looks more like a market waiting for clarity on sustainable cash flows...